Why Gilead Sciences Stock Is Jumping Today
Shares of Gilead Sciences ( GILD 7.46%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year financial results following market close on Tuesday.
Why Gilead Sciences (GILD) Stock Is Trading Up Today
What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue,
Maxim Group Reaffirms Their Hold Rating on Gilead Sciences (GILD)
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Shares of Gilead Sciences Inc. advanced 7.46% to $103.31 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.27% to 6,051.97 and Dow Jones Industrial Average falling 0.
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Piper Sandler Sticks to Its Buy Rating for Gilead Sciences (GILD)
Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of
RBC Capital raises Gilead Sciences stock price target to $90
RBC Capital Markets adjusted its outlook on Gilead Sciences (NASDAQ:GILD) stock, increasing the price target to $90 from the previous $84 while maintaining a Sector Perform rating. The adjustment reflects the firm's assessment of Gilead's potential growth drivers post-2025 and its performance exiting 2024.
Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...
U.S. News & World Report1mon
Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs
Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs By Blake Brittain (Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute ...
Yahoo Finance4d
Gilead Sciences (GILD) Q4 Earnings: What To Expect
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7.
Nasdaq16d
Looking At Gilead Sciences's Recent Unusual Options Activity
Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...